VAXXON SRP E. COLI
Commercial- Indications
- Bacterial infections in livestock
Company intelligence / Profile preview
Vaxxinova
Willmar/Worthington, Minnesota, USAvaxxinova.com ↗
- Ownership
- Private
- Employees
- ~155
- Development stage
- Commercial
01
Overview
Vaxxinova’s SRP® technology-based vaccines have been commercialized for multiple livestock pathogens. The company recently achieved USDA approval for the first-ever importation of a live avian metapneumovirus vaccine into the U.S., marking a significant regulatory milestone. No human clinical trials as this is an animal health company.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineLive vaccineInactivated vaccineAutogenous vaccineWhole-cell bacterin vaccine
- Industry
- Veterinary
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Long-term partnerships with veterinarians/livestock producers globallyAcquisition partnership with Dechra regarding the Avishield portfolio
Beyond the preview
Go deeper on Vaxxinova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxxinova.